280 related articles for article (PubMed ID: 19784522)
1. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population.
Jentschke M; Soergel P; Lange V; Kocjan B; Doerk T; Luyten A; Petry KU; Poljak M; Hillemanns P
Int J Gynecol Cancer; 2012 Jul; 22(6):1050-6. PubMed ID: 22740006
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
6. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
9. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
10. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
Huang S; Erickson B; Tang N; Mak WB; Salituro J; Robinson J; Abravaya K
J Clin Virol; 2009 Jul; 45 Suppl 1():S19-23. PubMed ID: 19651364
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
[TBL] [Abstract][Full Text] [Related]
14. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test.
Tang N; Huang S; Erickson B; Mak WB; Salituro J; Robinson J; Abravaya K
J Clin Virol; 2009 Jul; 45 Suppl 1():S25-8. PubMed ID: 19651365
[TBL] [Abstract][Full Text] [Related]
15. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears.
Cuzick J; Ambroisine L; Cadman L; Austin J; Ho L; Terry G; Liddle S; Dina R; McCarthy J; Buckley H; Bergeron C; Soutter WP; Lyons D; Szarewski A
J Med Virol; 2010 Jul; 82(7):1186-91. PubMed ID: 20513082
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
18. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
19. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]